Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma
Developing · 1 item · 1 language ninjs package →first 12.09.2026 12:01 · last 12.09.2026 12:01 UTC
| Time | Lang | Type | Headline | Desk | Rights |
|---|---|---|---|---|---|
| 12.09 12:01 | en | Standard story | Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma | Science Official | link only |